These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21777638)

  • 41. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a live attenuated dengue virus vaccine using reverse genetics.
    Blaney JE; Durbin AP; Murphy BR; Whitehead SS
    Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
    Wichmann O; Vannice K; Asturias EJ; de Albuquerque Luna EJ; Longini I; Lopez AL; Smith PG; Tissera H; Yoon IK; Hombach J
    Vaccine; 2017 Oct; 35(42):5535-5542. PubMed ID: 28893477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
    Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
    Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current progress in dengue vaccines.
    Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
    J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.
    Barban V; Munoz-Jordan JL; Santiago GA; Mantel N; Girerd Y; Gulia S; Claude JB; Lang J
    Virology; 2012 Aug; 429(2):91-8. PubMed ID: 22542002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Working towards dengue as a vaccine-preventable disease: challenges and opportunities.
    Shrivastava A; Tripathi NK; Dash PK; Parida M
    Expert Opin Biol Ther; 2017 Oct; 17(10):1193-1199. PubMed ID: 28707486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T
    Curr Opin Mol Ther; 2004 Aug; 6(4):443-50. PubMed ID: 15468603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
    Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
    Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.
    Halstead SB
    Am J Trop Med Hyg; 2016 Oct; 95(4):741-745. PubMed ID: 27352870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
    Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
    Martinez DR; Metz SW; Baric RS
    Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-generation dengue vaccines: novel strategies currently under development.
    Durbin AP; Whitehead SS
    Viruses; 2011 Oct; 3(10):1800-14. PubMed ID: 22069516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.
    Valdés I; Gil L; Romero Y; Castro J; Puente P; Lazo L; Marcos E; Guzmán MG; Guillén G; Hermida L
    Clin Vaccine Immunol; 2011 Mar; 18(3):455-9. PubMed ID: 21209159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospects for a dengue virus vaccine.
    Whitehead SS; Blaney JE; Durbin AP; Murphy BR
    Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.